

December 21, 2018

Completion of injection to all patients in first cohort in Clinical Trials of RBM-007

We are pleased to announce that the injection to all of 3 patients in the first cohort was completed in phase I/IIa trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD).

This PI/IIa trial is an open label, non-controlled, dose-escalating study assessing mainly the safety and tolerability of a single intravitreal injection of RBM-007 in approximately nine subjects. Up to now, no safety issue has been observed.

We will start the next dose cohort after reviewing the safety in the first cohort with an observation period of about one month.

See [ClinicalTrials.gov](https://clinicaltrials.gov) for more information.

<https://clinicaltrials.gov/ct2/show/NCT03633084>

Contact: <https://www.ribomic.com/en/contact.html>